Search Results - "Poon, R.T"

THU-13 Systemic therapy for HCC: State-of-art by Poon, R.T

Get full text

Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial by Pinyol, R, Montal, R, Takayama, T, Chau, G.-Y, Mazzaferro, V, Roayaie, S, Lee, H.C, Poon, R.T.-P, Kokudo, N, Zhang, Z, Bassaganyas, L, Torrecilla, S, Moeini, A, Rodriguez-Carunchio, L, Gane, E, Verslype, C, Croitoru, A.E, Cillo, U, de la Mata, M, Lupo, L, Strasser, S, Park, J.-W, Camps, J, Solé, M, Thung, S.N, Villanueva, A, Pena, C, Meinhart, G, Bruix, J, Llovet, J.M

Get full text

Treatment strategy of hepatocellular carcinoma located in right posterior section in patients with liver cirrhosis: right hepatectomy vs right posterior sectionectomy- a case matched single centre experience by Yip, V.S, Cheung, T.T, Chok, K.S, Dai, W.C, Tsang, S.H, Chan, A.C, Chan, S.C, Poon, R.T, Lo, C.M

Get full text

Recurrence determined 10-year survival of hepatocellular carcinoma after hepatectomy by Wong, T.C, Cheung, T.T, Chok, K.S, Chan, A.C, Dai, W.C, Chan, S.C, Poon, R.T, Fan, S.T, Lo, C.M

Get full text

AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study by Yau, T, Wong, H, Chan, P, Yao, T.J, Cheung, T.T, Fan, S.T, Poon, R.T

“…Background The combination of bevacizumab and erlotinib has shown promising clinical outcomes as the first-line treatment for patients with advanced…”
Get full text

676 MORTALIN-P53 INTERACTION IN CANCER CELLS IS STRESS DEPENDENT AND CONSTITUTES A NOVEL TARGET FOR LIVER CANCER THERAPY by Lu, W.-J, Lee, N.P, Kaul, S.C, Poon, R.T, Wadhwa, R, Luk, J.M

Get full text

665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) by Yau, T, Yen, C.-J, Chen, P.-J, Chau, Y, Lencioni, R, Kallender, H, Ottesen, L.H, Poon, R.T.-P

Get full text

1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY by Llovet, J.M, Decaens, T, Raoul, J.-L, Boucher, E, Kudo, M, Chang, C, Kang, Y.-K, Assenat, E, Lim, H.-Y, Boige, V, Mathurin, P, Fartoux, L, Lin, D.-Y, Bruix, J, Poon, R.T, Sherman, M, Blanc, J.-F, Finn, R, Tak, W.-Y, Chao, Y, Ezzeddine, R, Liu, D, Walters, I, Park, J.-W

Get full text

[485] ROLE OF HBV GENOTYPES, CORE PROMOTER/PRECORE MUTATIONS AND HBVDNA LEVELS ON HEPATOCARCINOGENESIS by Yuen, M.F, Tanaka, Y, Shinkai, N, Poon, R.T, Fung, J, Wong, O.K, Yuen, I.C, Mizokami, M, Lai, C.L

Get full text

47LBA Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma by Yau, T, Chan, P, Cheung, F.Y, Lee, A.S, Yau, T.K, Choo, S.P, Lau, J, Wong, J.S, Fan, S.T, Poon, R.T

Get full text

Upper GI 21 by Súilleabháin, C.B.Ó., Poon, R.T.-P., Ooi, G.C., Tso, W.-K., Yong, J.L., Fan, S.-T.

“…Aim: To evaluate the long‐term survival benefit of TACE in patients with inoperable hepatocellular carcinoma and determine prognostic factors by analysis of…”
Get full text

AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma by Xu, M Z, Chan, S W, Liu, A M, Wong, K F, Fan, S T, Chen, J, Poon, R T, Zender, L, Lowe, S W, Hong, W, Luk, J M

“…Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently…”
Get full text

PS-022 - Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial by Pinyol, R., Montal, R., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H.C., Poon, R.T.-P., Kokudo, N., Zhang, Z., Bassaganyas, L., Torrecilla, S., Moeini, A., Rodriguez-Carunchio, L., Gane, E., Verslype, C., Croitoru, A.E., Cillo, U., de la Mata, M., Lupo, L., Strasser, S., Park, J.-W., Camps, J., Solé, M., Thung, S.N., Villanueva, A., Pena, C., Meinhart, G., Bruix, J., Llovet, J.M.

Get full text

Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial by Poon, R T-P, Yeung, C, Liu, C-L, Lam, C-M, Yuen, W-K, Lo, C-M, Tang, A, Fan, S-T

“…Background: Previous studies suggested that somatostatin given before endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of…”
Get full text